SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential ...

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in ...

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be ...

Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―― Live and ...

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data ...

Canada could benefit from looking at how Argentina and others have approached gene editing in livestock and its effect on ...

A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 90 days.

Phase 3 PEAK results in 2nd-line GIST patients expected in November; pivotal APEX results in AdvSM patients expected in December Breakthrough Therapy Designation granted for bezuclastinib; New Drug Ap ...

A Czech scientist has contributed to understanding the function of the thymus—the training center of the immune system. T ...

When a young Sealaska intern walking a beach in July 2022 found the first evidence of European green crab presence in Alaska ...

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Amazon is shaking up the natural-foods grocer with robots in the backroom and Pepsi outside the exit in its push for a bigger ...